DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for pycnodysostosis — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePycnodysostosis maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for pycnodysostosis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
cathepsin K (CTSK) — CTSK is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5Z5O · 1.92 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Pycnodysostosis is caused by mutations in the cathepsin K (CTSK) gene. A 2014 study of 16 patients from 14 families identified five missense mutations (M1I, I249T, L7P, D80Y, D169N), one nonsense mutation (R312X), and a 301 bp Alu insertion in intron 7. Only L7P and I249 had been described before. All mutations were homozygous, and most families came from regions with high consanguineous marriage rates. Patients with the M1I mutation, which likely leads to complete absence of the protein, had fractures at younger ages than other patients. The typical finding of acroosteolysis was absent in two patients even though other patients carrying the same mutations had it. No previously described hot spot mutations were found; L7P and R312X were the most frequent.
A 1974 report of six patients described symptoms not previously recognised in pycnodysostosis: varying degrees of respiratory distress, a tendency to vomit, and long soft palates. One patient died at 21 months from vomiting and pulmonary aspiration; autopsy showed normal lungs. The authors state that the vital prognosis is usually considered good but may be poorer in the first years of life. Radiographic findings were inconsistent: one patient showed slight increase in bony substance in the distal phalanges, another showed both breakdown and new bone formation in the ungual processes, and a third had cyst-like defects in some ungual tufts. The authors note these conditions are incompletely understood.
A 2021 case report describes a 22-month-old boy with extreme short stature (height standard deviation score −4.05) and disproportionate skeletal dysplasia. Magnetic resonance imaging showed pituitary hypoplasia, and an insulin-like growth factor generation test demonstrated biochemical responsiveness to growth hormone therapy. After 18 months of growth hormone therapy, his height improved to −2.25 SD with an annualised growth velocity of 9.65 cm per year. The authors state that growth hormone deficiency is a common association in pycnodysostosis, secondary to pituitary hypoplasia, and that the greatest benefit from growth hormone therapy is seen in children started at a young age.
What remains missing is prospective data on long-term outcomes of growth hormone therapy beyond height, including fracture rates and respiratory complications. No controlled trials exist. Patient stratification by mutation type and age at treatment initiation has not been systematically studied. Funding for natural history studies and for trials that measure functional endpoints rather than height alone is lacking.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Orphanet Journal of Rare Diseases · 2014 · 46 citations · open access
Cathepsin K analysis in a pycnodysostosis cohort: demographic, genotypic and phenotypic features
AbstractBACKGROUND: To characterize cathepsin K (CTSK) mutations in a group of patients with pycnodysostosis, who presented with either short stature or atypical fractures to pediatric endocrinology or dysmorphic features to pediatric genetics clinics. METHODS: Seven exons and exon/intron boundaries of CTSK gene for the children and their families were amplified with PCR and sequenced. Sixteen patients from 14 families with pycnodysostosis, presenting with typical dysmorphic features, short stature, frequent fractures and osteosclerosis, were included in the study. RESULTS: We identified five missense mutations (M1I, I249T, L7P, D80Y and D169N), one nonsense mutation (R312X) and one 301 bp insertion in intron 7, which is revealed as Alu sequence; among them, only L7P and I249 were described previously. The mutations were homozygous in all cases, and the families mostly originated from the region where consanguineous marriage rate is the highest. Patients with M1I mutation had fractures, at younger ages than the other pycnodysostosis cases in our cohort which were most probably related to the severity of mutation, since M1I initiates the translation, and mutation might lead to the complete absence of the protein. The typical finding of pycnodysostosis, acroosteolysis, could not be detected in two patients, although other patients carrying the same mutations had acroosteolysis. Additionally, none of the previously described hot spot mutations were seen in our cohort; indeed, L7P and R312X were the most frequently detected mutations. CONCLUSIONS: We described a large cohort of pycnodysostosis patients with genetic and phenotypic features, and, first Alu sequence insertion in pycnodysostosis.
PYCNODYSOSTOSIS: Six Cases with New Symptoms and an Autopsy
AbstractAbstract. Lykkegaard Nielsen, E. (Department of Paediatrics, Sundby Hospital, Copenhagen, Denmark.) Pycnodysostosis. Six cases with new symptoms and an autopsy. Acta Paediatr Scand, 63: 437, 1974.–Six patients with pycnodysostosis, all of whom had characteristic case‐histories, are presented. Five of the patients had symptoms which have not hitherto been recognized in this condition. They all had varying degrees of respiratory distress, tendency to vomit and long soft palates. One of the patients died at the age of 21 months on account of vomiting and pulmonary aspiration. Autopsy revealed normal conditions in the lungs. The vital prognosis is usually stated to be good in this disease, but this study shows that during the first years of life it is possibly poorer. Occurrence of progressive acmteolysis in pycnodysostosis has been discussed previously. In one of the patients in this material slight increase in the bony substance in the distal phalanges of the fingers was observed on repeated radiografic examination while in another both break‐down and new bone formation were observed in the processus unguiculares. In a third patient cyst‐like defects in some of the ungual tufts of the fingers were present. These conditions are thus incompletely elucidated at present.
AACE Clinical Case Reports · 2021 · 9 citations · open access
Pycnodysostosis: A Growth Hormone Responsive Skeletal Dysplasia
AbstractOBJECTIVE: Pycnodysostosis is commonly associated with growth hormone (GH) deficiency and responds well to GH therapy with achievement of normal or near-normal height and restoration of body proportions. CASE REPORT: A 22-month-old extremely short (-4.05 height standard deviation score) disproportionate boy with skeletal dysplasia presented to clinic. Skeletal survey, genetic panel, magnetic resonance imaging, and an insulin-like growth factor generation tests were performed. RESULTS: . Uniquely among skeletal dysplasias, GH deficiency is a common association, secondary to pituitary hypoplasia. Magnetic resonance imaging confirmed pituitary hypoplasia and he subsequently underwent an insulin-like growth factor generation test that demonstrated biochemical responsiveness to GH therapy. This was thought to be safer than a classic GH stimulation test, in view of his very small size. Subsequently, his height has markedly improved on GH therapy. His height is now -2.25 SD, with an annualized growth velocity of 9.65 cm/y over a period of 18 months . CONCLUSION: It is important to consider GH therapy in children with pycnodysostosis, with the greatest benefit seen in children started at a young age.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
